Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats

Effects of systemically administered abaloparatide, an osteoanabolic PTHrP analog, as an adjuvant therapy for spinal fusion in rats

Abstract Background Abaloparatide is a parathyroid hormone receptor agonist that increases bone formation and reduces vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis. Animal studies indicate abaloparatide stimulates vertebral bone formation and enhances bony bridgi...

Full description

Bibliographic Details
Main Authors: Heike Arlt, Tatiana Besschetnova, Michael S. Ominsky, Douglas C. Fredericks, Beate Lanske
Format: Article
Language:English
Published: Wiley 2021-03-01
Series:JOR Spine
Subjects:
arthrodesis
bone formation
bone‐forming agent
fusion mass
spine surgery
Online Access:https://doi.org/10.1002/jsp2.1132

Internet

https://doi.org/10.1002/jsp2.1132

Similar Items